Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery
References (12)
- et al.
First-pass metabolism of cyclosporin by the gut
Lancet
(1991) - et al.
Factors influencing drug absorption and drug availability
- et al.
Clinical Pharmacokinetics: Concepts and Applications
Individual variation in first-pass metabolism
Clin. Pharmacokinet.
(1993)- et al.
Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
- et al.
Identification of glucocorticoid-inducible cytochromes P-450 in intestinal mucosa of rats and man
J. Clin. Invest.
(1987)
There are more references available in the full text version of this article.
Cited by (189)
Quantitative Assessment of the Impact of Crohn's Disease on Protein Abundance of Human Intestinal Drug-Metabolising Enzymes and Transporters
2022, Journal of Pharmaceutical SciencesCitation Excerpt :Verapamil bioavailability increased by two fold while no change was observed with digoxin and rosuvastatin. Drugs that are substrates of more than one protein, especially those suggested to work in synergy, such as CYP3A4 and P-gp,82–84 are expected to incur higher changes in bioavailability.85–88 Limitations of this study include the use of pooled samples, which does not afford a measure of variability between patients.
Gutsy science: In vitro systems of the human intestine to model oral drug disposition
2022, Pharmacology and TherapeuticsFormulation technologies and advances for oral delivery of novel nitroimidazoles and antimicrobial peptides
2020, Journal of Controlled ReleaseEx-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA
2018, European Journal of Pharmaceutical SciencesMicrofluidic Organ-on-a-Chip Models of Human Intestine
2018, Cellular and Molecular Gastroenterology and HepatologyBiomedical Metal–Organic Framework Materials: Perspectives and Challenges
2023, Advanced Functional Materials
Copyright © 1996 Published by Elsevier B.V.